Barrier analysis of periocular drug delivery to the posterior segment

Journal of Controlled Release

Volumn 148, Issue 1, 2010, Pages 42-48

  Ranta, Veli Pekka ^b   Mannermaa, Eliisa ^b   Lummepuro, Kirsi ^a   Subrizi, Astrid ^a   Laukkanen, Antti ^a,d   Antopolsky, Maxim ^a   Murtomäki, Lasse ^a,c   Hornof, Margit ^a   Urtti, Arto ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c AALTO UNIVERSITY   (Finland)

^d UPM Group   (Finland)

Author keywords

Ocular drug delivery; Periocular; Pharmacokinetic simulation; Posterior segment; Retinal drug delivery; RPE; Subconjunctival; Trans scleral drug delivery

Indexed keywords

OCULAR DRUG DELIVERY; PERIOCULAR; POSTERIOR SEGMENT; RETINAL DRUG DELIVERY; RPE; SUBCONJUNCTIVAL; TRANS-SCLERAL DRUG DELIVERY;

ALDEHYDES; BLOOD; DRUG DELIVERY; GLUCOSE; HEMODYNAMICS; MACROMOLECULES; OLIGONUCLEOTIDES; OPHTHALMOLOGY; PHARMACOKINETICS;

DRUG DOSAGE;

CARBOXYFLUORESCEIN; CELECOXIB; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; GADOLINIUM PENTETATE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PREDNISOLONE;

ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CHOROID; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; NONHUMAN; PRIORITY JOURNAL; RETINA NEUROEPITHELIAL LAYER; SCLERA; STEADY STATE; VITREOUS BODY;

ANIMALS; BIOLOGICAL AVAILABILITY; CATTLE; CHOROID; DEXTRANS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; METABOLIC CLEARANCE RATE; PERMEABILITY; POSTERIOR EYE SEGMENT; RETINAL PIGMENT EPITHELIUM; SCLERA;

EID: 78649529307     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.028     Document Type: Article

References (44)

1. Friedman D.S., O'Colmain B.J., Munoz B., Tomany S.C., McCarty C., de Jong R.T., Nemesure B., Mitchell P., Kempen J. Eye diseases prevalence research group, prevalence of agerelated macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
2. Urtti A., Pipkin J.D., Rork G., Repta A.J. Controlled drug delivery devices for experimental ocular studies with timolol. 1. In vitro release studies. Int. J. Pharm. 1990, 61:235-240.
3. Maurice D.M., Mishima S. Ocular pharmacokinetics. Pharmacology of the Eye 1984, 19-116. Springler-Verlag, Berlin. M.L. Sears (Ed.).
4. Del Amo E., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 2008, 13:135-143.
5. Kim H., Robinson M.R., Lizak M., Tansey G., Lutz R.J., Yuan P., Wang N.S., Csaky K.G. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci. 2004, 45:2722-2731.
6. Conrad J.M., Robinson J.R. Mechanisms of anterior segment absorption of pilocarpine following subconjunctival injection in albino rabbits. J. Pharm. Sci. 1977, 69:875-884.
7. Ahmed I., Patton T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 1985, 26:584-587.
8. Chan J.E., Pridgen T.A., Csaky K.G. Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat. Exp. Eye Res. 2010, 90:501-506.
9. Liu X., Li K.S., Jeong E.K. Ocular pharmacokinetics study of a corticosteroid by 19F MR. Exp. Eye Res. 2010, 91:347-352.
10. Kim S.H., Csaky K.G., Wang N.S., Lutz R.J. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm. Res. 2008, 25:512-520.
11. Prausnitz M.R., Noonan J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998, 87:1479-1488.
12. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 2000, 41:1181-1185.
13. Maurice D.M., Polgar J. Diffusion across the sclera. Exp. Eye Res. 1977, 25:577-582.
14. Olsen T.W., Edelhauser H.F., Lim J.I., Geroski D.H. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 1995, 36:1893-1903.
15. Pitkänen L., Ranta V.P., Moilanen H., Urtti A. Permeability of retinal pigment epithelium: effect of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 2005, 46:641-646.
16. Robinson M.R., Lee S.S., Kim H., Kim S., Lutz R.J., Galban C., Bungay P.M., Yuan P., Wang N.S., Kim J., Csaky K.G. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 2006, 82:479-487.
17. Lee T.W.Y., Robinson J.R. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther. 2004, 20:43-53.
18. Lee T.W.Y., Robinson J.R. Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection. J. Ocul. Pharmacol. Therap. 2009, 25:29-37.
19. Amrite A.C., Edelhauser H.E., Kompella U.B. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci. 2008, 49:320-332.
20. Balachandran R.K., Barocas V.H. Computer modeling of drug delivery to the posterior eye: effect of active transport and choroidal blood flow. Pharm. Res. 2008, 25:2685-2695.
21. Gabhann F.M., Demetriades A.M., Deering T., Packer J.D., Shah S.M., Duh E., Campochiaro P.A., Popel A.S. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Engn. 2007, 35:615-630.
22. Ranta V.P., Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 2006, 58:1164-1181.
23. Saltzman W.M., Radomsky M.L., Whaley K.J., Cone R.A. Antibody diffusion in human cervical mucus. Biophys. J. 1994, 66:508-515.
24. Thorne R.G., Lakkaraju A., Rodriguez-Boulan E., Nicholson C. In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc. Natl Acad. Sci. USA 2008, 105:8416-8421.
25. Chary S.R., Jain R.K. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc. Natl Acad. Sci. USA 1989, 86:5385-5389.
26. Brown E.B., Boucher Y., Nasser S., Jain R.K. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc. Res. 2004, 67:231-236.
27. Törnquist P. Capillary permeability in cat choroid, studied with the single injection technique (II). Acta Physiol. Scand. 1979, 106:425-430.
28. Bill A. Capillary permeability to and extravascular dynamics of myoglobin, albumin and gammaglobulin in the uvea. Acta Physiol. Scand. 1968, 73:204-219.
29. Bill A., Törnquist P., Alm A. Permeability of the intraocular blood vessels. Trans. Ophthalmol. Soc. UK 1980, 100:332-336.
30. Duvvuri S., Gandhi M.D., Mitra A.K. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye Res. 2003, 27:345-353.
31. Durairaj C., Kim S.J., Edelhauser H.F., Shah J.C., Kompella U.B. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest. Ophthalmol. Vis. Sci. 2009, 50:4887-4897.
32. Majumdar S., Hippalgaonkar K., Srirangam R. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. Drug Metab. Dispos. 2009, 37:1718-1725.
33. Liu X., Li K.S., Jeong E.K. Ocular pharmacokinetics study of a corticosteroid by 19F MR. Exp. Eye Res. 2010, 91:347-352.
34. Berthe P., Baudouin C., Garraffo R., Hofmann P., Taburet A.M., Lapalus P. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. Invest. Ophthalmol. Vis. Sci. 1994, 24:1038-1045.
35. Snyder M.R., Reid J.M., Pulido J.S., Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007, 114:855-859.
36. Kim H., Csaky K.G., Chan C.C., Bungay P.M., Lutz R.J., Dedrick R.L., Yuan P., Rosenberg J., Grillo-Lopez A.J., Wilson W.H., Robinson M.R. The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. 2006, 82:760-766.
37. Watson P.G., Young P.D. Scleral structure, organization and disease. Exp. Eye Res. 2004, 78:609-623.
38. Bernstein M.H., Hollenberg M.J. Fine structure of the choriocapillaris and retinal capillaries. Invest. Ophthalmol. 1965, 4:1016-1025.
39. Sugita A., Hamasaki M., Higashi R. Regional difference in fenestration of choroidal capillaries in Japanese monkey eye. Jpn J. Ophthalmol. 1982, 26:47-52.
40. Guymer R.H., Bird A.C., Hageman GS G.S. Cytoarchitecture of choroidal capillary endothelial cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:1660-1666.
41. Melamed S., Ben-Sira I., Ben-Shaul Y. Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit-a freeze-fracturing study. Br. J. Ophthalmol. 1980, 64:537-543.
42. Matsuoka T. Freeze-fracture studies of the choriocapillary endothelium. 1. Three dimensional visualization of the fenestral diaphragm. Nippon Ganka Gakkai Zasshi 1983, 87:1065-1076.
43. Matsuoka T. Freeze-fracture studies on the choriocapillary endothelium. 3. Three-dimensional ultrastructure of environment surrounding the endothelium. Nippon Ganka Gakkai Zasshi 1985, 89:1221-1235.
44. Einmahl S., Savoldelli M., D'Hermies F., Tabatabay C., Gurny R., Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Vis. Sci. 2002, 43:1533-1539.